Axicabtagene ciloleucel
| Clinical data | |
|---|---|
| Trade names | Yescarta |
| Other names | KTE-C19, Axi-cel |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618003 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| DrugBank | |
| UNII | |
| KEGG | |
Axicabtagene ciloleucel, sold under the brand name Yescarta, is a medication used for the treatment for large B-cell lymphoma that has failed conventional treatment. T cells are removed from a person with lymphoma and genetically engineered to produce a specific T-cell receptor. The resulting chimeric antigen receptor T cells (CAR-Ts) that react to the cancer are then given back to the person to populate the bone marrow. Axicabtagene treatment carries a risk for cytokine release syndrome (CRS) and neurological toxicities.
Due to CD19 being a pan-B cell marker, the T-cells that are engineered to target CD19 receptors on the cancerous B cells also influence normal B cells, except some plasma cells.